Paula Kushlan, MD
Medical Oncology · Palo Alto
- Medicare standing
- 2 flags on the record
- Listed below.
- Plans that list them
- 12
- 1 carrier
- Office
- 1
On the public record
- Medicare does not list them as allowed to order and refer
- California licence: Delinquent
Offices
1 location
Plans that list them
12 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Kushlan’s office at (209) 603-8524 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence G31863 · Delinquent
Licence status: Delinquent · since 1976 · expires 2025-05-31 · Harvard Medical School.
License renewal fee has not been paid. No practice is permitted.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Medical Oncology
Drugs they prescribed that Part D paid
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their 88 Part D prescriptions in 2023.
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Year by year
| 2023 | 88 | 34 | 0% (0) | None | $6,553 |
| 2022 | 503 | 148 | 3% (15) | None | $637,457 |
| 2021 | 758 | 185 | 4% (27) | 12% | $833,353 |
| 2020 | 992 | 216 | 4% (40) | 11% | $658,612 |
| 2019 | 987 | 229 | 4% (42) | 10% | $264,281 |
| 2018 | 1,056 | 237 | 2% (25) | 9% | $362,693 |
| 2017 | 1,088 | 226 | 4% (46) | 11% | $507,108 |
| 2016 | 1,106 | 230 | 3% (35) | 12% | $467,107 |
| 2015 | 944 | 208 | 4% (36) | 14% | $267,908 |
| 2014 | 995 | 181 | 5% (47) | 18% | $154,072 |
| 2013 | 941 | 167 | 8% (78) | None | $141,490 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Exemestane | 13 | $2,506 | $193 |
| Anastrozole | 34 | $892 | $26 |
2022: 7 drugs
| Exemestane | 41 | $12,651 | $309 |
| Anastrozole | 171 | $4,981 | $29 |
| Raloxifene | 31 | $4,703 | $152 |
| Tamoxifen Citrate | 74 | $2,173 | $29 |
| Gabapentin | 22 | $888 | $40 |
| Omeprazole | 11 | $153 | $14 |
| Prochlorperazine Maleate | 11 | $142 | $13 |
2021: 12 drugs
| Tagrisso | 13 | $274,976 | $21,152 |
| Lynparza | 12 | $185,524 | $15,460 |
| Exemestane | 72 | $18,784 | $261 |
| Anastrozole | 237 | $9,780 | $41 |
| Eliquis | 14 | $8,223 | $587 |
| Raloxifene | 43 | $6,140 | $143 |
| Tamoxifen Citrate | 89 | $5,078 | $57 |
| Gabapentin | 50 | $2,295 | $46 |
| Hydromorphone | 12 | $531 | $44 |
| Prochlorperazine Maleate | 24 | $262 | $11 |
| Mirtazapine | 12 | $243 | $20 |
| Lorazepam | 17 | $131 | $8 |
2020: 16 drugs
| Exemestane | 95 | $39,017 | $411 |
| Anastrozole | 283 | $10,480 | $37 |
| Eliquis | 15 | $10,106 | $674 |
| Raloxifene | 45 | $9,308 | $207 |
| Tamoxifen Citrate | 87 | $7,695 | $88 |
| Hydromorphone | 12 | $1,481 | $123 |
| Letrozole | 26 | $1,378 | $53 |
| Gabapentin | 68 | $1,327 | $20 |
| Acyclovir | 20 | $985 | $49 |
| Prochlorperazine Maleate | 37 | $520 | $14 |
| Dexamethasone | 14 | $354 | $25 |
| Lorazepam | 20 | $227 | $11 |
| Ondansetron | 20 | $226 | $11 |
| Hydrocodone-Acetaminophen | 14 | $107 | $8 |
| Alendronate | 16 | $104 | $7 |
| Sulfamethoxazole-Trimethoprim | 19 | $100 | $5 |
2019: 15 drugs
| Exemestane | 97 | $41,630 | $429 |
| Raloxifene | 55 | $10,304 | $187 |
| Anastrozole | 282 | $9,970 | $35 |
| Xarelto | 15 | $9,263 | $618 |
| Tamoxifen Citrate | 84 | $7,821 | $93 |
| Gabapentin | 50 | $892 | $18 |
| Hydromorphone | 12 | $628 | $52 |
| Letrozole | 25 | $599 | $24 |
| Prochlorperazine Maleate | 34 | $329 | $10 |
| Dexamethasone | 22 | $293 | $13 |
| Lorazepam | 43 | $216 | $5 |
| Pantoprazole | 12 | $123 | $10 |
| Ondansetron | 11 | $86 | $8 |
| Nystatin | 11 | $76 | $7 |
| Escitalopram | 11 | $22 | $2 |
2018: 13 drugs
| Exemestane | 87 | $57,173 | $657 |
| Raloxifene | 52 | $11,066 | $213 |
| Anastrozole | 312 | $8,676 | $28 |
| Tamoxifen Citrate | 80 | $6,952 | $87 |
| Gabapentin | 63 | $1,066 | $17 |
| Letrozole | 40 | $515 | $13 |
| Dexamethasone | 36 | $469 | $13 |
| Acyclovir | 22 | $330 | $15 |
| Ondansetron | 17 | $265 | $16 |
| Prochlorperazine Maleate | 26 | $239 | $9 |
| Lorazepam | 60 | $211 | $4 |
| Hydrocodone-Acetaminophen | 13 | $152 | $12 |
| Prednisone | 11 | $89 | $8 |
2017: 18 drugs
| Ibrance | 20 | $225,895 | $11,295 |
| Tarceva | 11 | $72,475 | $6,589 |
| Exemestane | 99 | $69,742 | $704 |
| Raloxifene | 60 | $10,859 | $181 |
| Tamoxifen Citrate | 105 | $6,184 | $59 |
| Anastrozole | 267 | $5,705 | $21 |
| Gabapentin | 85 | $951 | $11 |
| Letrozole | 37 | $601 | $16 |
| Lorazepam | 63 | $285 | $5 |
| Ondansetron | 18 | $257 | $14 |
| Hydrocodone-Acetaminophen | 17 | $238 | $14 |
| Omeprazole | 15 | $210 | $14 |
| Dexamethasone | 17 | $204 | $12 |
| Prochlorperazine Maleate | 34 | $191 | $6 |
| Prednisone | 12 | $154 | $13 |
| Acyclovir | 11 | $135 | $12 |
| Trazodone | 18 | $126 | $7 |
| Sulfamethoxazole-Trimethoprim | 11 | $62 | $6 |
2016: 15 drugs
| Tarceva | 24 | $148,268 | $6,178 |
| Ibrance | 13 | $136,281 | $10,483 |
| Exemestane | 141 | $64,350 | $456 |
| Raloxifene | 78 | $16,289 | $209 |
| Anastrozole | 271 | $6,463 | $24 |
| Tamoxifen Citrate | 99 | $4,342 | $44 |
| Gabapentin | 80 | $1,114 | $14 |
| Letrozole | 26 | $658 | $25 |
| Lorazepam | 82 | $428 | $5 |
| Hydrocodone-Acetaminophen | 13 | $297 | $23 |
| Omeprazole | 26 | $238 | $9 |
| Dexamethasone | 14 | $225 | $16 |
| Prochlorperazine Maleate | 22 | $169 | $8 |
| Ondansetron | 13 | $157 | $12 |
| Alendronate | 18 | $142 | $8 |
2015: 13 drugs
| Tarceva | 19 | $126,477 | $6,657 |
| Exemestane | 117 | $69,015 | $590 |
| Raloxifene | 69 | $18,970 | $275 |
| Anastrozole | 238 | $4,800 | $20 |
| Tamoxifen Citrate | 83 | $3,720 | $45 |
| Evista | 11 | $2,193 | $199 |
| Gabapentin | 86 | $802 | $9 |
| Letrozole | 31 | $496 | $16 |
| Alendronate | 22 | $290 | $13 |
| Lorazepam | 60 | $270 | $5 |
| Dexamethasone | 17 | $247 | $15 |
| Omeprazole | 16 | $223 | $14 |
| Prochlorperazine Maleate | 22 | $145 | $7 |
2014: 15 drugs
| Exemestane | 150 | $70,716 | $471 |
| Evista | 33 | $11,363 | $344 |
| Raloxifene | 27 | $8,059 | $298 |
| Anastrozole | 176 | $5,896 | $33 |
| Tamoxifen Citrate | 86 | $3,131 | $36 |
| Gabapentin | 74 | $779 | $11 |
| Lorazepam | 114 | $639 | $6 |
| Omeprazole | 39 | $406 | $10 |
| Oxycodone | 14 | $366 | $26 |
| Dexamethasone | 22 | $317 | $14 |
| Alendronate | 21 | $267 | $13 |
| Ondansetron | 24 | $264 | $11 |
| Letrozole | 15 | $236 | $16 |
| Prochlorperazine Maleate | 22 | $163 | $7 |
| Prednisone | 13 | $78 | $6 |
2013: 16 drugs
| Exemestane | 177 | $71,587 | $404 |
| Evista | 62 | $22,286 | $359 |
| Anastrozole | 143 | $5,178 | $36 |
| Fentanyl | 23 | $2,246 | $98 |
| Tamoxifen Citrate | 91 | $2,052 | $23 |
| Gabapentin | 56 | $814 | $15 |
| Letrozole | 11 | $659 | $60 |
| Megestrol Acetate | 12 | $648 | $54 |
| Omeprazole | 26 | $646 | $25 |
| Lorazepam | 51 | $314 | $6 |
| Oxycodone | 13 | $309 | $24 |
| Alendronate | 22 | $265 | $12 |
| Hydrocodone-Acetaminophen | 16 | $258 | $16 |
| Dexamethasone | 20 | $153 | $8 |
| Ondansetron | 15 | $117 | $8 |
| Prednisone | 12 | $34 | $3 |
Money from drug and device companies
$25 in 2023
| 2023 | 1 | 1 | None | $25 |
| 2022 | 1 | 1 | None | $32 |
| 2019 | 1 | 1 | None | $12 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Pfizer | Ibrance | $25 | 1 payment
|
See the published payment
| Pfizer | Education · 2023-08-02 | Ibrance | $25 |
See earlier years (2022, 2019)
2022: $32
| Pfizer | Ibrance | $32 | 1 payment
|
2019: $12
| Pfizer | Ibrance | $12 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 84.1 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1689783839
- Licence
- CA G31863California G31863: Delinquent · expires 2025-05-31
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2006-08-30
- NPI last updated
- 2020-03-03
- NPI record certified
- 2020-03-03
This is when the NPI record was last certified, not a medical board exam.